• SPX
  • $5,983.99
  • -0.29 %
  • -$17.36
  • DJI
  • $43,910.98
  • -0.86 %
  • -$382.15
  • N225
  • $39,037.03
  • -0.86 %
  • -$338.84
  • FTSE
  • $8,025.77
  • -1.22 %
  • -$99.42
  • IXIC
  • $19,281.40
  • -0.09 %
  • -$17.36
Akebia Therapeutics, Inc. (AKBA) Stock Price, News & Analysis

Akebia Therapeutics, Inc. (AKBA) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.96

-$0.03

(-1.51%)

Day's range
$1.88
Day's range
$2
50-day range
$1.24
Day's range
$2.02
  • Country: US
  • ISIN: US00972D1054
52 wk range
$0.8
Day's range
$2.48


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -9.78
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (AKBA)
  • Company Akebia Therapeutics, Inc.
  • Price $1.96
  • Changes Percentage (-1.51%)
  • Change -$0.03
  • Day Low $1.88
  • Day High $2.00
  • Year High $2.48

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/12/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $6.50
  • High Stock Price Target $7.00
  • Low Stock Price Target $6.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.22
  • Trailing P/E Ratio -4.82
  • Forward P/E Ratio -4.82
  • P/E Growth -4.82
  • Net Income $-51,925,000

Income Statement

Quarterly

Annual

Latest News of AKBA

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.